Cerulean Pharma is a private biopharmaceutical company focused on the development
of novel, nanotechnology-based therapeutics in the areas of oncology, cardiovascular,
autoimmune and inflammatory diseases.
Cerulean is pursuing three key strategies to achieve leadership in Nanopharmaceuticals:
Cerulean has assembled a world-class management team, board of directors and
scientific advisory board that collectively have a significant track record
of business building, product development and scientific breakthroughs. Cerulean
was founded in 2006 and is located in Cambridge, Massachusetts.
Cerulean's Lead Candidate Presented in Talk on Nanoparticle Delivery at ASCO Annual Meeting
Cerulean’s CRLX101 Nanopharmaceutical Phase 2 Clinical Trial Achieves Primary Endpoint
Translational Data on Cerulean’s CRLX101 Polymeric Nanoparticle Candidate Published in PNAS
Cerulean Pharma to Discuss Pre-Clinical and Clinical Results of Nanopharmaceutical CRLX101 at AACR Meeting
Cerulean Pharma to Showcase Nanopharmaceutical Platform at Nanotechnology Innovation Summit
Cerulean to Present on Nanopharmaceutical Platform at Two Major European Conferences
Dr. Fetzer to Highlight Nanopharmaceutical Advancement at BioPharm America Event
Dr. Yitong Dong
Dr. Yitong Dong has recently been awarded funding to study custom composite nanocrystals, which could help to create advanced quantum communication technologies. Learn more about this project in this interview.
Roey Elnathan, Ph.D.
We take a closer look at the fusion of nanotechnology and CAR-T therapy through our interview with Dr. Roey Elnathan about a new approach that harnesses the capabilities of nanoneedles to efficiently deliver genetic materials to target cells.
In this interview, Laura-Isabelle, the Director of Sales at Photon etc., talks to AzoNano about how spectral imaging can help improve the next generation of solar cells.
The Verifire™ interferometer system provides fast and reliable measurements of surface form error.
Discover the compact, fast rotary table V-610 for precision testing and manufacture.
The Diamond Interaction Chamber (DIXC) is integral to the NanoGenizer high-pressure homogenizer.